References

ppharm

Педиатрическая фармакология

Pediatric pharmacology

1727-57762500-3089

Издательство «ПедиатрЪ»

10.15690/pf.v12i1.1250

ppharm-471

Research Article

ВАКЦИНАЦИЯ В СОВРЕМЕННОМ МИРЕ

VACCINATION

ВИРУС ПАПИЛЛОМЫ ЧЕЛОВЕКА. ПРОФИЛАКТИКА ВПЧ-АССОЦИИРОВАННЫХ ЗАБОЛЕВАНИЙ

HUMAN PAPILLOMA VIRUS. PREVENTION OF HPV-ASSOCIATED DISEASES

Шахтахтинская

Ф. Ч.

Shakhtakhtinskaya

F. C.

кандидат медицинских наук, старший научный сотрудник отделения вакцинопрофилактики детей с отклонениями в состоянии здоровья НИИ Профилактической педиатрии и восстановительного лечения ФГБНУ «Научный центр здоровья детей»

dr.firuza@yandex.ru

Намазова-Баранова

Л. С.

Namazova-Baranova

L. S.

Таточенко

В. К.

Tatochenko

V. K.

Новикова

Д. А.

Novikova

D. A.

Ткаченко

Н. Е.

Tkachenko

N. E.

Научный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Center of Children's Health, Moscow, Russian FederationRussian Federation

2015

21082015

1217478

2015

Шахтахтинская Ф.Ч., Намазова-Баранова Л.С., Таточенко В.К., Новикова Д.А., Ткаченко Н.Е.

Shakhtakhtinskaya F.C., Namazova-Baranova L.S., Tatochenko V.K., Novikova D.A., Tkachenko N.E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pedpharma.ru/jour/article/view/471

High prevalence of sexually transmitted diseases among the population attracts attention of specialists in all countries due to frequent development of complications resulting in reproductive dysfunction. The article presents one of the urgent issues of modern medicine — papillomavirus infection, which is the most common sexually transmitted disease. 70–80% of the sexually active persons contract human papilloma virus at one point. HPV induces a broad range of oncological reproductive diseases, including cervical, vulvar, vaginal and anal cancer and anogenital condylomae, which are observed both in men and women. The only reliable method of preventing papillomavirus infection is vaccination. The authors present new data on the use of the quadrivalent vaccine, including a new immunization pattern for 9–14-years-old girls.

папилломавирусная инфекциявирус папилломы человекарак шейки маткианогенитальная областьпрофилактикавакцинацияквадривалентная вакцинадевочкиподростки

papillomavirus infectionhuman papilloma viruscervical canceranogenital regionpreventionvaccinationquadrivalent vaccinegirlsadolescents

References1

de Villiers E.-M., Fauquet C., Broker T. R., Bernard H.-U., zur Hausen H. Phylogenetic tree containing sequences of 118 papillomavirus types. Virology. 2004; 324: 17–24.

de Villiers E.-M., Fauquet C., Broker T.R., Bernard H.-U., zur Hausen H. Phylogenetic tree containing sequences of 118 papillomavirus types. Virology. 2004; 324: 17−24.

WHO/IVB Database, as at 29 September 2014.

Centers for Disease Control and Prevention (CDC). Genital HPV infection (fact sheet). URL: cdc.gov/std/hpv/hpv-fact-sheet.pdf. Accessed November 11, 2011.

Centers for Disease Control and Prevention (CDC). Genital HPV infection (fact sheet). Available at: cdc.gov/std/hpv/hpv-fact-sheet.pdf. Accessed November 11, 2011.

Hampl M. et al. Obstet Gynecol. 2006; 108: 1361–1368.

Castle P. E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A. C., Bratti M. C. J Infect Dis. 2005; 191: 1808–1816.

Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C. J Infect Dis. 2005; 191: 1808–1816.

Anhang R., Goodman A., Goldie S. J. CA: A Cancer. J Clin. 2004; 54: 248–259.

Anhang R., Goodman A., Goldie S.J. CA: A Cancer. J Clin. 2004; 54: 248–259.

Forman D. et al. Vaccine. 2012; 30 (Suppl. 5): F12–23.

Forman D. et al. Vaccine. 2012; 30 (Suppl. 5): F12−23.

World Health Organization. URL: http://www.who.int/whr/1995/media_centre/executive_summary1/en/index.htm

World Health Organization. Available at: http://www.who.int/whr/1995/media_centre/executive_summary1/en/index.htm

Greer C. E. et al. J Clin Microbiol. 1995; 33: 2058–2063.

Greer C.E. et al. J Clin Microbiol. 1995; 33: 2058−2063.

Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals, 2007. World Health Organization website. URL: http://whqlibdoc.who.int/hq/2007/WHO _IVB_07.05_eng.pdf

Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals, 2007. World Health Organization website. Available at: http://whqlibdoc.who.int/hq/2007/WHO _IVB_07.05_eng.pdf

Health Protection Agency (HPA). Health Protect Rep. 2012; 6: 9–15. URL: http://www.hpa.org.uk/HPR/archives/2012/hpr2212.pdf.

Health Protection Agency (HPA). Health Protect Rep. 2012; 6: 9−15. Available at: http://www.hpa.org.uk/HPR/archives/2012/hpr2212.pdf.

Palefsky J. M. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J NatI Cancer Inst Monogr. 1998; 23: 15–18.

Palefsky J.M. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J NatI Cancer Inst Monogr. 1998; 23: 15–18.

Palefsky J. M. et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001; 183 (3): 383–91.

Palefsky J.M. et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001; 183 (3): 383–91.

Xi L. F. et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res. 1998; 58 (17): 3839–44.

Xi L.F. et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res.1998; 58 (17): 3839–44.

Critchlow C. W. et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS. 1998; 12 (10): 1177–84.

Critchlow C.W. et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS. 1998; 12 (10): 1177–84.

Асламазян Л. К., Намазова Л. С. Генитальные кондиломы. Распространенность, этиология, лечение и профилактика. Педиатри ческая фармакология. 2008; 5 (5): 14–17.

Aslamazyan L.K., Namazova L.S. Genital warts. The prevalence, etiology, treatment and prevention. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2008; 5 (5): 14–17.

Намазова Л. С. О новой вакцине, предотвращающей рак шейки матки. Педиатрическая фармакология. 2006; 3 (6): 55–57.

Namazova L.S. A new vaccine that prevents cervical cancer. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2006; 3 (6): 55–57.

Ferlay J., Shin H. R., Bray F., Forman D., Mathers C. D., Parkin D. Globocan-2008. Cancer Incidence and Mortality Worldwide. IARC CancerBase. Lyon, France. 2010; 10.

Ferlay J., Shin H.R., Bray F., Forman D., Mathers C.D., Parkin D. Globocan-2008. Cancer Incidence and Mortality Worldwide. IARC CancerBase. Lyon, France. 2010; 10.

Роговская С. И. Распространенность папилломавирусной инфек ции в России. Эпидемиология и вакцинопрофилактика. 2012; 1 (62).

Rogovskaya S.I. Prevalence of HPV infection in Russia. Epidemiologiya i vaktsinoprofilaktika = Epidemiology and vaccination. 2012; 1 (62).

Globocan-2010. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. Accessed on 09/09/2012.

Munoz N., Mendez F., Posso H. et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis. 2004; 15: 2077–87.

Micali С., Nasca М. К., Innocenzi О., Schwaгtz R. A. PeniIe сапсег. J Ат Acad Оегmatol. 2006; 54 (3): 369–91.

Micali С., Nasca М.К., Innocenzi О., Schwaгtz R.A. PeniIe сапсег. J Ат Acad Оегmatol. 2006; 54 (3): 369–91.

Brown D. R. et al. J Clin Microbiol. 1999; 37: 3316–3322.

Brown D.R. et al. J Clin Microbiol. 1999; 37: 3316–3322.

Гомберг М. А. Причин достаточно. Медицинский вестник. 2014; 25 (674).

Gomberg M.A. Reasons enough. Meditsinskii vestnik = Medical Bulletin. 2014; 25 (674).

Инструкция по применению препарата Церварикс.

Instruktsiya po primeneniyu preparata Tservariks [Application on the drug Cervarix].

Инструкция по применению препарата Гардасил.

Instruktsiya po primeneniyu preparata Gardasil [Application on the drug Gardasil].

Таточенко В. К. Иммунопрофилактика-2014. Москва: ПедиатрЪ. 2014.

Tatochenko V.K. Immunoprofilaktika-2014 [Immunization 2014]. Moscow, Pediatr"", 2014.

Brown D. The clinical impact of cross-protection to nonvaccine HPV types. Presented at: 27th International Papillomavirus Conference; September 17–22, 2011. Berlin, Germany. 2011. Abstract P-18.13.

Brown D. The clinical impact of cross-protection to non-vaccine HPV types. Presented at: 27th International Papillomavirus Conference; September 17–22, 2011. Berlin, Germany. 2011. Abstract P-18.13.

The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. Lancet. 2007; 369: 1861–68.

The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomized controlled trial. BMJ. 2010; 340: 3493.

Garland S. M. The Australian Experience With the Human Papillomavirus Vaccine. Clinical Therapeutics. 2014; 36 (1).

Garland S.M. The Australian Experience With the Human Papillomavirus Vaccine. Clinical Therapeutics. 2014; 36 (1).

Donovan B. et al. Lancet Infect Dis. 2011; 11: 39–44.

Grulich A. E. et al. IPV 2011. Berlin. 2011. Abstract O-04.01.

Grulich A.E. et al. IPV 2011. Berlin. 2011. Abstract O-04.01.

Read T et al. Sex Transm Infect. 2011; 87 (7): 544–7.

Read T et al. Sex Transm Infect. 2011; 87 (7): 544−7.

Fairley et al. Sex Transm Infect. 2009; 85: 499–502 .

Fairley et al. Sex Transm Infect. 2009; 85: 10.

The authors declare that there are no conflicts of interest present.